EQS-Adhoc: Newron Pharmaceuticals SpA: Newron initiiert erste potenziell zulassungsrelevante Studie mit Evenamide bei Patienten mit Schizophrenie

DGAP-Ad-hoc: Newron Pharmaceuticals S.p.A. / Schlagwort(e): Studie Newron initiiert erste potenziell zulassungsrelevante Studie mit Evenamide bei Patienten mit Schizophrenie 06.09.2021 / 07:00 CET/CEST Veröffentlichung

Related Keywords

Australia , Bresso , Lombardia , Italy , Japan , Milan , United States , Israel , Colombia , United Arab Emirates , Canada , Switzerland , Italian , Israeli , Australians , Swiss , Ravi Anand , Newron Unternehmenseigenem , Shimon Conway , Caroline Bergmann , Evenamide , Worldcom Newron Stefan Weber , Mc Services , Lavoie Health Science , Development Or Marketing , For Research , Six Swiss Exchange , Newron Pharmaceuticals , Supernus Pharmaceuticals , Newron Pharmaceuticals Spa Via Antonio Meucci , Study Newron , Cest Publication , Placebo Kontrollierte Study , Treatment Does , Chief Medical , Antipsychotika Does , Currently Evenamide , About Evenamide , Begleittherapie For , From Newron Unternehmenseigenem , Newron Was , Enzymes Or Truck , Antipsychotika Start , Further Studies , About Newron Pharmaceuticals , Newron Partner Zambon , Meiji Seika , More Information , Worldcom Newron Stefan Weber Ceo , Fti Consulting , Worldcom Switzerland Valentine , Irf Reputation , Worldcom Important , This Document , Drugs For , Statements Contained , Future Events , Plans Or Expectations , Shops Do Not , Statements Or The , Are Quoted , Registration Or An Exemption , Purchase Or The , Newron Pharmaceuticals Aktie , Dgap , Dhoc , Onewron , Pharmaceuticals , Nitiiert , Berste , Otenziell , Ulassungsrelevante , Studie , Patienten , Schizophrenie ,